Pidnarulex Phase 1b Enrollment Complete: Novel Mechanism, No Data, Three Phases From Approval

Senhwa Completes Enrollment for CX-5461 Phase 1b Trial

Senhwa Biosciences, Inc. announced the completion of enrollment in its Phase 1b expansion trial evaluating pidnarulex (CX-5461) monotherapy. The trial focuses on patients with advanced solid tumors harboring BRCA1/2, PALB2, or other homologous recombination deficiency (HRD)-associated alterations. With enrollment now complete, the study will proceed to data review, database lock, and statistical analysis, with the Clinical Study Report (CSR) anticipated in the first quarter of 2027. This milestone is expected to inform future decisions regarding indication prioritization, biomarker-based patient selection, potential combination strategies, and support global licensing efforts for CX-5461.

• The Phase 1b trial evaluated CX-5461 monotherapy in a heavily pretreated patient population with advanced DNA repair-deficient solid tumors, specifically including pancreatic, breast, and ovarian cancers. Patients had received a median of six prior lines of therapy (range, 1-14), with most having previously received multiple standard-of-care treatments, including PARP inhibitors, underscoring a significant unmet medical need.
• CX-5461 is a first-in-class G-quadruplex stabilizer, designed to exploit vulnerabilities in DNA repair-deficient tumors through a mechanism distinct from PARP inhibition. Preliminary data presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting showed promising antitumor activity, with an exploratory advanced ovarian cancer cohort achieving a disease control rate of nearly 60% among 16 BRCA-mutated patients, all of whom had prior PARP inhibitor therapy.
• The completion of enrollment and the upcoming Clinical Study Report will be crucial for guiding the next stages of CX-5461's clinical development. The findings are expected to inform decisions on biomarker-based patient selection, potential combination strategies with agents like PARP inhibitors, immunotherapies, or antibody-drug conjugates, and support Senhwa's global licensing and strategic partnering efforts, positioning CX-5461 as a potential later-line option for HRD-associated cancers.

Addressing the Unmet Need in Advanced HRD Solid Tumors

Current treatment approaches for advanced solid tumors with homologous recombination deficiency (HRD) — particularly PARP inhibitor (PARPi)-based regimens — face several clinically significant limitations that constrain long-term efficacy and patient management. These challenges span resistance biology, tolerability, and diagnostic infrastructure, collectively underscoring the unmet need for improved therapeutic strategies in this setting.

• Acquired resistance to PARP inhibitors: The predominant mechanism of PARPi resistance is restoration of homologous recombination proficiency through secondary genetic or epigenetic events — including reversion mutations in BRCA1 or BRCA2, or reversal of BRCA1 promoter methylation. In a pan-cancer cohort, reversion mutations were identified at an overall frequency of 1.7% (11/654), occurring exclusively across three HRR genes: BRCA1 (3.8%), BRCA2 (3.5%), and PALB2 (2.0%). Additional resistance mechanisms — such as loss of DNA end resection inhibition (via 53BP1/REV7/RIF1/Shieldin) or altered replication fork protection (PTIP/EZH2), increased drug efflux, and induction of senescent or mesenchymal cell states — have been described in ovarian cancer models, though few have been confirmed in clinical samples.

• Significant hematological toxicity: PARPi administration is associated with substantially elevated risks of hematologic adverse events. Anemia was the most frequently reported all-grade event (49.2%) and the leading ≥Grade 3 adverse event (25.0%). Compared to non-PARPi regimens, PARPis significantly increased risk of all-grade anemia (RR = 2.15), neutropenia (RR = 1.50), and thrombocytopenia (RR = 2.59), as well as ≥Grade 3 anemia (RR = 5.43), neutropenia (RR = 1.70), and thrombocytopenia (RR = 5.42) — all statistically significant. These toxicities frequently necessitate dose modifications or treatment discontinuation, compromising therapeutic continuity.

• Limitations of commercial HRD testing: Existing commercial HRD assays are constrained by high rates of inconclusive results, significant cost burdens, and an inability to capture functional resistance mechanisms — limiting their utility in both patient selection and resistance monitoring.

• Risk of secondary malignancies with long-term PARPi use: PARP inhibitors carry a low but clinically relevant risk of secondary hematologic malignancies, including acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS), with an overall incidence of approximately 0.9% among patients treated with niraparib — a safety signal that warrants ongoing surveillance in long-term survivors.

CX-5461's Targeted Approach for HRD-Positive Tumors

Pidnarulex (CX-5461) clinical development has been anchored in a biomarker-driven patient selection strategy centered on homologous recombination deficiency (HRD). The pivotal multicentre phase I trial (CCTG IND.231) specifically enrolled patients with advanced solid tumors enriched for DNA repair deficiencies, with defective homologous recombination investigated as the primary predictive biomarker of response. A Canadian phase I trial further refined this approach by evaluating pidnarulex in breast and ovarian cancer patients with known germline BRCA1/2 mutations, where objective responses were observed in approximately 14% of patients — predominantly among those with confirmed defective homologous recombination.

Beyond BRCA1/2, the patient selection framework has been extended to encompass deficiencies in additional DNA damage response (DDR) pathway components. Clinical evaluation of pidnarulex in solid tumors deficient in BRCA2 and PALB2 provided the basis for the FDA granting Fast Track Designation for early-stage studies in BRCA1-, BRCA2-, and PALB2-mutated cancers. More broadly, patients with deficiencies across multiple DDR pathways — not limited to canonical BRCA mutations — were identified as potential responders in the phase I program, reflecting the drug's proposed mechanism of exploiting replication stress in HRD-compromised tumor cells.

The synthetic lethality hypothesis underlying this patient selection strategy has received direct clinical validation. Upon disease progression following initial responses in germline BRCA2 and PALB2 carriers, reversion mutations in the respective genes were detected, confirming that resistance emerged through restoration of homologous recombination function. This finding not only substantiates the mechanistic rationale for HRD as a predictive biomarker but also reinforces the specificity of the synthetic lethal interaction driving pidnarulex's antitumor activity in this molecularly defined population.

Preliminary Safety and Efficacy of Pidnarulex (CX-5461)

Published clinical safety data for pidnarulex (CX-5461) derives primarily from a phase I trial conducted in patients with advanced solid tumors. Across 10 dose levels ranging from 50 to 650 mg/m², the agent was generally well tolerated, with a recommended phase II dose established at 475 mg/m² administered on days 1, 8, and 15 every 4 weeks. The trial enrolled 40 patients enriched for DNA-repair deficiencies, including those with BRCA1/2 deficiency or broader defects in DNA damage response pathways.

The principal dose-limiting toxicity identified was phototoxicity. In vitro characterization confirmed that UV sensitization is attributable to the CX-5461 chemotype itself and occurs independently of its G-quadruplex synthetic lethality mechanism — an important pharmacological distinction with implications for patient management and future formulation strategies.

From an efficacy standpoint, objective responses were observed in 14% of the 40 treated patients, with responses occurring predominantly in individuals harboring defective homologous recombination. Notably, reversion mutations in PALB2 and BRCA2 were detected upon disease progression following initial response in germline mutation carriers, both corroborating the synthetic lethal mechanism of action and providing a molecular basis for acquired resistance to pidnarulex.

Pidnarulex (CX-5461) in Future HRD Combination Strategies

Combination strategies for HRD-positive advanced solid tumors are rapidly evolving beyond PARP inhibitor monotherapy, with recent trials exploring rational mechanistic pairings to overcome resistance and deepen response. Approaches under active investigation span immune checkpoint co-inhibition, antiangiogenic combinations, and DNA damage response (DDR) pathway co-targeting.

• PARP inhibitor + immune checkpoint inhibition: The POLAR trial evaluated maintenance pembrolizumab plus olaparib following platinum-based chemotherapy in biomarker-stratified metastatic pancreatic cancer. In cohort A (BRCA1/2- or PALB2-mutated HRD), the 6-month PFS rate reached 64% (95% CI: 49–82%), with median PFS of 8.3 months, median OS of 28 months, and 3-year OS of 44% (95% CI: 28–69%). Separately, a Phase II study (NCT04169841) is evaluating olaparib (300 mg BID) combined with durvalumab (1500 mg Q4W) and tremelimumab (75 mg Q4W) in solid tumors harboring HRR gene mutations, followed by durvalumab maintenance for up to 24–36 months.

• PARP inhibitor + antiangiogenic therapy: In newly diagnosed advanced ovarian cancer with confirmed HRD positivity, maintenance olaparib combined with antiangiogenic therapy demonstrated a significant PFS benefit over antiangiogenic therapy alone, with no new safety signals identified relative to monotherapy experience.

• CHK1 inhibitor + PARP inhibitor: The combination of SRA737 (a CHK1 inhibitor) with a PARP inhibitor induced tumor regression in patient-derived xenograft models of high-grade serous ovarian cancer, including both PARP inhibitor–resistant and CCNE1-amplified tumors — addressing two clinically significant resistance contexts.

• WEE1 inhibitor + ATR inhibitor ± PD-L1 blockade: Co-targeting WEE1 and ATR produced in vivo tumor remission through STING pathway activation, driving type I interferon signaling and CD8+ T cell recruitment. Upregulation of PD-L1 observed with this combination provides mechanistic rationale for the addition of anti-PD-L1 therapy to further potentiate antitumor immunity.

Pidnarulex: Advancing a Targeted Approach in HRD Cancers

The completion of enrollment for pidnarulex's Phase 1b expansion trial marks a crucial juncture for Senhwa Biosciences and the broader oncology community. Pidnarulex (CX-5461) represents a fascinating example of evolving drug mechanism understanding and targeted therapy development. Initially explored for its RNA polymerase I inhibitory effects, more recent research indicates its primary action as a G-quadruplex stabilizer, causing DNA damage and selectively inducing lethality in cells with homologous recombination deficiencies (HRD), such as those with BRCA1/2 or PALB2 mutations. This synthetic lethal approach is a cornerstone of precision oncology, aiming to exploit specific vulnerabilities in cancer cells.

The prior Phase I trial established clinical proof-of-concept, showing responses predominantly in HRD patients and confirming the underlying synthetic lethal mechanism through observed resistance via BRCA2 and PALB2 reversion mutations. This strong mechanistic and early clinical validation positions pidnarulex as a promising candidate for a defined patient population. Strategically, this reinforces a biomarker-driven development path, which can streamline clinical trials and potentially lead to a more focused and effective market entry.

However, the path forward is not without considerations. The anticipated Clinical Study Report in Q1 2027 means a significant wait for comprehensive data, which could impact the drug's development timeline and competitive positioning. Furthermore, phototoxicity emerged as a dose-limiting toxicity in earlier studies, a factor that will need careful management in future trials and clinical practice. The observed resistance mechanisms, particularly reversion mutations in key HRD genes, highlight the need for ongoing research into combination therapies or sequential treatments to maintain long-term efficacy. Despite these challenges, the completion of this trial moves pidnarulex closer to potentially offering a new, targeted option for patients with HRD-driven advanced solid tumors, especially those who may have exhausted other therapies, including PARP inhibitors.